Is the TCH-P regimen active in early or locally advanced HER2-positive breast cancer? Results of a retrospective study

被引：0
|
作者：
Longo, Raffaele [1 ]
Thiebaut, Victoire [1 ]
Legros, Pierre-Olivier [1 ]
Campitiello, Marco [1 ]
Plastino, Francesca [1 ]
Goetz, Christophe [2 ]
Margineanu, Bogdan [3 ]
Pujois, Julie [3 ]
Gunther, Michel [3 ]
Egea, Julie [1 ]
Wendel, Chloe [1 ]
机构：
[1] CHR Metz Thionville, Div Med Oncol, 1 Allee Chateau, F-57085 Ars Laquenexy, France
[2] CHR Metz Thionville, Clin Res Support Unit, Ars Laquenexy, France
[3] CHR Metz Thionville, Div Gynecol, Ars Laquenexy, France
来源：
ACTA ONCOLOGICA | 2022年 / 61卷 / 11期
关键词：
OPEN-LABEL; PLUS TRASTUZUMAB; LAPATINIB; SAFETY; CHEMOTHERAPY; EFFICACY; RECOMMENDATIONS; MULTICENTER; PERTUZUMAB; THERAPY;
D O I：
10.1080/0284186X.2022.2132115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1394 / 1399
页数：6
相关论文
共 50 条
  • [21] A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer
    Yang, Zhi
    Fu, Wei-Da
    Gu, Hua-Yan
    Ding, Jia-Ling
    Guo, Gui-Long
    CANCER MANAGEMENT AND RESEARCH, 2025, 17 : 441 - 460
  • [22] Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective
    McGee, Sharon F.
    Clemons, Mark
    Savard, Marie-France
    CURRENT ONCOLOGY, 2022, 29 (06) : 4125 - 4137
  • [23] Advances in the management of HER2-positive early breast cancer
    Baselga, Jose
    Coleman, Robert E.
    Cortes, Javier
    Janni, Wolfgang
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 119 : 113 - 122
  • [24] Early HER2-Positive Breast Cancer: Current Treatment and Novel Approaches
    Ban, Marija
    Mise, Branka Petric
    Vrdoljak, Eduard
    BREAST CARE, 2020, 15 (06) : 560 - 568
  • [25] Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis
    Cui, Manlu
    Fu, Juan
    Li, Qiuyun
    BMC CANCER, 2024, 24 (01)
  • [26] How We Treat Locally Advanced HER2-Positive Breast Cancer
    Exman, Pedro
    Pernas, Sonia
    Tolaney, Sara M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 271 - 280
  • [27] Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
    Harbeck, Nadia
    BREAST, 2022, 62 : S12 - S16
  • [28] Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
    von Minckwitz, Gunter
    Schneeweiss, Andreas
    Loibl, Sibylle
    Salat, Christoph
    Denkert, Carsten
    Rezai, Mahdi
    Blohmer, Jens U.
    Jackisch, Christian
    Paepke, Stefan
    Gerber, Bernd
    Zahm, Dirk M.
    Kummel, Sherko
    Eidtmann, Holger
    Klare, Peter
    Huober, Jens
    Costa, Serban
    Tesch, Hans
    Hanusch, Claus
    Hilfrich, Joern
    Khandan, Fariba
    Fasching, Peter A.
    Sinn, Bruno V.
    Engels, Knut
    Mehta, Keyur
    Nekljudova, Valentina
    Untch, Michael
    LANCET ONCOLOGY, 2014, 15 (07) : 747 - 756
  • [29] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [30] Targeted Therapy in HER2-Positive Breast Cancer
    Thill, Marc
    Kraft, Clayton
    Friedrich, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) : 295 - 302
12345